What is Barrington Research’s Estimate for ANIK Q1 Earnings?

Anika Therapeutics, Inc. (NASDAQ:ANIK) – Stock analysts at Barrington Research issued their Q1 2026 EPS estimates for shares of Anika Therapeutics in a report issued on Thursday, March 13th. Barrington Research analyst M. Petusky forecasts that the biotechnology company will post earnings per share of ($0.16) for the quarter. Barrington Research currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for Anika Therapeutics’ current full-year earnings is ($0.84) per share. Barrington Research also issued estimates for Anika Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2027 earnings at ($0.45) EPS.

Separately, StockNews.com upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th.

Anika Therapeutics Stock Up 1.3 %

Shares of Anika Therapeutics stock opened at $16.11 on Monday. Anika Therapeutics has a twelve month low of $14.95 and a twelve month high of $29.12. The company has a 50-day simple moving average of $16.90 and a two-hundred day simple moving average of $19.40. The stock has a market capitalization of $235.95 million, a price-to-earnings ratio of -2.42 and a beta of 0.95.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. The business had revenue of $30.60 million during the quarter, compared to analyst estimates of $29.00 million.

Hedge Funds Weigh In On Anika Therapeutics

Several hedge funds have recently bought and sold shares of the company. Connors Investor Services Inc. increased its holdings in Anika Therapeutics by 8.0% in the 4th quarter. Connors Investor Services Inc. now owns 11,560 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 861 shares during the period. Los Angeles Capital Management LLC increased its holdings in Anika Therapeutics by 9.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 11,700 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 980 shares during the period. Wellington Management Group LLP increased its holdings in Anika Therapeutics by 3.7% in the 4th quarter. Wellington Management Group LLP now owns 39,785 shares of the biotechnology company’s stock valued at $655,000 after buying an additional 1,407 shares during the period. HighTower Advisors LLC increased its holdings in Anika Therapeutics by 11.3% in the 3rd quarter. HighTower Advisors LLC now owns 15,883 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 1,615 shares during the period. Finally, R Squared Ltd bought a new position in Anika Therapeutics in the 4th quarter valued at about $27,000. 91.53% of the stock is owned by institutional investors.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.